Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/2/2010

e treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C.  The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statem
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
2. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... SAN DIEGO , Oct. 21, 2014 /PRNewswire/ ... announced today the latest genomics research centers to ... the Salk Institute, the National Cancer Institute (NCI), ... National Sequencing Center). Before Irys, obtaining a comprehensive ... because next generation sequencing (NGS) does not deliver ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... Inc. announced today that it has raised $19.2 million ... GBS Venture Partners and BioPacificVentures participated in the round. ... from additional investors in a second closing, scheduled for ... us to take essential steps for the development of ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... into a multi-year research collaboration agreement through the Stanford ... collaborative and innovative research projects in the early phases ... Dr. Paul Chew, Senior Vice President, U.S. Chief Science ...
Cached Medicine Technology:CoDa Therapeutics Closes $19 Million Series B Financing Round 2CoDa Therapeutics Closes $19 Million Series B Financing Round 3CoDa Therapeutics Closes $19 Million Series B Financing Round 4Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 2Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 3
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... PUNTA GORDA, Fla., April 25 North ... closed on Cypress,Professional Center, 25097 Olympia Avenue, ... medical office building is located near,Charlotte Regional ... practice. The building is being converted to ...
... in partnership with,others to fight the malaria epidemic, ... treatable, malaria continues to devastate communities in,tropical regions ... World Health Organization (WHO), the malaria epidemic causes,debilitating ... and kills,more than one million people each year ...
... Thoratec,Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts,today announced that it ... quarter of 2008 on Thursday, May 1., ... discuss its financial,results and operating activities to all ...
... funds ... clinic., New guide to low-income dental clinics in the ... teeth, gum,disease, extractions, root canals -- the very words give us ... to regularly visit our,dentists for preventive maintenance., Upper Willamette Valley ...
... helping doctors diagnose and treat lung cancer were ... Conference jointly organized by the European Society for ... the Study of Lung Cancer (IASLC) in Geneva, ... Friday 25th April, 16:30), Israeli researchers from Rosetta ...
... AX Series Delivers MyFluVaccine Portal a Next-generation Server Load ... Balancer Platform for Web Application Delivery, ... today,announced that FFF Enterprises, the nation,s largest distributor of ... Series Advanced Traffic Manager to provide a Web application,delivery ...
Cached Medicine News:Health News:Oaks Development Group Acquires Medical Office Building in Punta Gorda, Florida 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 3Health News:Thoratec Schedules First Quarter 2008 Conference Call, Webcast 2Health News:Smiles. Made Fresh Daily 2Health News:New genetic techniques to combat lung cancer 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 3
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: